http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Wed, 03 Jun 2026 09:24:35 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Intl+Ratings/JPMorgan+Downgrades+Daiichi+Sankyo+Company%2C+Limited+%284568%3AJP%29+%28DSNKY%29+to+Neutral/26596665.html <p>JPMorgan analyst Seiji Wakao downgraded Daiichi Sankyo Company, Limited (4568:JP) (OTC: DSNKY) from Overweight to Neutral with a price target of JPY2,750.00 (from JPY3,700.00).</p><p>The analyst comments: “Based on 4Q FY2025 results and the medium-term plan, we revise down our earnings estimates, lower our price target to ¥2,750 (previously ¥3,700), and downgrade our rating to Neutral. The outlooks for operating cash flow and operating profit announced in the medium-term plan (FY2026-30) were below our expectations. As before, we view the results of clinical trials evaluating Datroway as a first-line (1L) treatment for lung cancer, including results from the AVANZAR study, which http://www.streetinsider.com/Intl+Ratings/JPMorgan+Downgrades+Daiichi+Sankyo+Company%2C+Limited+%284568%3AJP%29+%28DSNKY%29+to+Neutral/26596665.html Wed, 03 Jun 2026 09:24:35 -0400 DSNKY http://www.streetinsider.com/Intl+Ratings/JPMorgan+Downgrades+Daiichi+Sankyo+Company%2C+Limited+%284568%3AJP%29+%28DSNKY%29+to+Neutral/26596665.html <p>JPMorgan analyst Seiji Wakao downgraded Daiichi Sankyo Company, Limited (4568:JP) (OTC: DSNKY) from Overweight to Neutral with a price target of JPY2,750.00 (from JPY3,700.00).</p><p>The analyst comments: “Based on 4Q FY2025 results and the medium-term plan, we revise down our earnings estimates, lower our price target to ¥2,750 (previously ¥3,700), and downgrade our rating to Neutral. The outlooks for operating cash flow and operating profit announced in the medium-term plan (FY2026-30) were below our expectations. As before, we view the results of clinical trials evaluating Datroway as a first-line (1L) treatment for lung cancer, including results from the AVANZAR study, which http://www.streetinsider.com/Intl+Ratings/JPMorgan+Downgrades+Daiichi+Sankyo+Company%2C+Limited+%284568%3AJP%29+%28DSNKY%29+to+Neutral/26596665.html Wed, 03 Jun 2026 09:24:35 -0400 DSNKY http://www.streetinsider.com/Downgrades/JPMorgan+Downgrades+Daiichi+Sankyo+Company%2C+Limited+%284568%3AJP%29+%28DSNKY%29+to+Neutral/26596665.html <p>JPMorgan analyst Seiji Wakao downgraded Daiichi Sankyo Company, Limited (4568:JP) (OTC: DSNKY) from Overweight to Neutral with a price target of JPY2,750.00 (from JPY3,700.00).</p><p>The analyst comments: “Based on 4Q FY2025 results and the medium-term plan, we revise down our earnings estimates, lower our price target to ¥2,750 (previously ¥3,700), and downgrade our rating to Neutral. The outlooks for operating cash flow and operating profit announced in the medium-term plan (FY2026-30) were below our expectations. As before, we view the results of clinical trials evaluating Datroway as a first-line (1L) treatment for lung cancer, including results from the AVANZAR study, which http://www.streetinsider.com/Downgrades/JPMorgan+Downgrades+Daiichi+Sankyo+Company%2C+Limited+%284568%3AJP%29+%28DSNKY%29+to+Neutral/26596665.html Wed, 03 Jun 2026 09:24:35 -0400 DSNKY http://www.streetinsider.com/Downgrades/JPMorgan+Downgrades+Daiichi+Sankyo+Company%2C+Limited+%284568%3AJP%29+%28DSNKY%29+to+Neutral/26596665.html <p>JPMorgan analyst Seiji Wakao downgraded Daiichi Sankyo Company, Limited (4568:JP) (OTC: DSNKY) from Overweight to Neutral with a price target of JPY2,750.00 (from JPY3,700.00).</p><p>The analyst comments: “Based on 4Q FY2025 results and the medium-term plan, we revise down our earnings estimates, lower our price target to ¥2,750 (previously ¥3,700), and downgrade our rating to Neutral. The outlooks for operating cash flow and operating profit announced in the medium-term plan (FY2026-30) were below our expectations. As before, we view the results of clinical trials evaluating Datroway as a first-line (1L) treatment for lung cancer, including results from the AVANZAR study, which http://www.streetinsider.com/Downgrades/JPMorgan+Downgrades+Daiichi+Sankyo+Company%2C+Limited+%284568%3AJP%29+%28DSNKY%29+to+Neutral/26596665.html Wed, 03 Jun 2026 09:24:35 -0400 DSNKY http://www.streetinsider.com/Analyst+Comments/JPMorgan+Downgrades+Daiichi+Sankyo+Company%2C+Limited+%284568%3AJP%29+%28DSNKY%29+to+Neutral/26596665.html <p>JPMorgan analyst Seiji Wakao downgraded Daiichi Sankyo Company, Limited (4568:JP) (OTC: DSNKY) from Overweight to Neutral with a price target of JPY2,750.00 (from JPY3,700.00).</p><p>The analyst comments: “Based on 4Q FY2025 results and the medium-term plan, we revise down our earnings estimates, lower our price target to ¥2,750 (previously ¥3,700), and downgrade our rating to Neutral. The outlooks for operating cash flow and operating profit announced in the medium-term plan (FY2026-30) were below our expectations. As before, we view the results of clinical trials evaluating Datroway as a first-line (1L) treatment for lung cancer, including results from the AVANZAR study, which http://www.streetinsider.com/Analyst+Comments/JPMorgan+Downgrades+Daiichi+Sankyo+Company%2C+Limited+%284568%3AJP%29+%28DSNKY%29+to+Neutral/26596665.html Wed, 03 Jun 2026 09:24:35 -0400 DSNKY http://www.streetinsider.com/Analyst+Comments/JPMorgan+Downgrades+Daiichi+Sankyo+Company%2C+Limited+%284568%3AJP%29+%28DSNKY%29+to+Neutral/26596665.html <p>JPMorgan analyst Seiji Wakao downgraded Daiichi Sankyo Company, Limited (4568:JP) (OTC: DSNKY) from Overweight to Neutral with a price target of JPY2,750.00 (from JPY3,700.00).</p><p>The analyst comments: “Based on 4Q FY2025 results and the medium-term plan, we revise down our earnings estimates, lower our price target to ¥2,750 (previously ¥3,700), and downgrade our rating to Neutral. The outlooks for operating cash flow and operating profit announced in the medium-term plan (FY2026-30) were below our expectations. As before, we view the results of clinical trials evaluating Datroway as a first-line (1L) treatment for lung cancer, including results from the AVANZAR study, which http://www.streetinsider.com/Analyst+Comments/JPMorgan+Downgrades+Daiichi+Sankyo+Company%2C+Limited+%284568%3AJP%29+%28DSNKY%29+to+Neutral/26596665.html Wed, 03 Jun 2026 09:24:35 -0400 DSNKY http://www.streetinsider.com/Press+Releases/Daiichi+Sankyo+Showcases+Progress+Across+Industry-Leading+Oncology+Portfolio+with+Latest+Research+Updates+at+ASCO/26560941.html <ul class="bwlistdisc"> <li> New analyses from five landmark trials of Enhertu® and Datroway® in breast and gastric cancer alongside pipeline data across other tumor types demonstrate continued oncology leadership </li> <li> Early phase trials-in-progress featuring potential medicines with novel mechanisms highlight the company’s commitment to identifying new breakthrough generating technologies for patients with cancer </li> </ul> <p> TOKYO--(BUSINESS WIRE)-- Daiichi Sankyo (TSE: 4568) will present new clinical research across its oncology portfolio with more than 25 abstracts in multiple cancers at the 2026 American Society of Clinical Oncology Annual Meeting (#ASCO26). </p><p> Data at ASCO will highlight the company’s progress toward advancing new standards of care for patients http://www.streetinsider.com/Press+Releases/Daiichi+Sankyo+Showcases+Progress+Across+Industry-Leading+Oncology+Portfolio+with+Latest+Research+Updates+at+ASCO/26560941.html Thu, 28 May 2026 07:00:00 -0400 4568 4568 DSNKY O.17791244 O.22492915 http://www.streetinsider.com/Press+Releases/Daiichi+Sankyo+Showcases+Progress+Across+Industry-Leading+Oncology+Portfolio+with+Latest+Research+Updates+at+ASCO/26560941.html <ul class="bwlistdisc"> <li> New analyses from five landmark trials of Enhertu® and Datroway® in breast and gastric cancer alongside pipeline data across other tumor types demonstrate continued oncology leadership </li> <li> Early phase trials-in-progress featuring potential medicines with novel mechanisms highlight the company’s commitment to identifying new breakthrough generating technologies for patients with cancer </li> </ul> <p> TOKYO--(BUSINESS WIRE)-- Daiichi Sankyo (TSE: 4568) will present new clinical research across its oncology portfolio with more than 25 abstracts in multiple cancers at the 2026 American Society of Clinical Oncology Annual Meeting (#ASCO26). </p><p> Data at ASCO will highlight the company’s progress toward advancing new standards of care for patients http://www.streetinsider.com/Press+Releases/Daiichi+Sankyo+Showcases+Progress+Across+Industry-Leading+Oncology+Portfolio+with+Latest+Research+Updates+at+ASCO/26560941.html Thu, 28 May 2026 07:00:00 -0400 4568 4568 DSNKY O.17791244 O.22492915 http://www.streetinsider.com/Press+Releases/Daiichi+Sankyo+Showcases+Progress+Across+Industry-Leading+Oncology+Portfolio+with+Latest+Research+Updates+at+ASCO/26560941.html <ul class="bwlistdisc"> <li> New analyses from five landmark trials of Enhertu® and Datroway® in breast and gastric cancer alongside pipeline data across other tumor types demonstrate continued oncology leadership </li> <li> Early phase trials-in-progress featuring potential medicines with novel mechanisms highlight the company’s commitment to identifying new breakthrough generating technologies for patients with cancer </li> </ul> <p> TOKYO--(BUSINESS WIRE)-- Daiichi Sankyo (TSE: 4568) will present new clinical research across its oncology portfolio with more than 25 abstracts in multiple cancers at the 2026 American Society of Clinical Oncology Annual Meeting (#ASCO26). </p><p> Data at ASCO will highlight the company’s progress toward advancing new standards of care for patients http://www.streetinsider.com/Press+Releases/Daiichi+Sankyo+Showcases+Progress+Across+Industry-Leading+Oncology+Portfolio+with+Latest+Research+Updates+at+ASCO/26560941.html Thu, 28 May 2026 07:00:00 -0400 4568 4568 DSNKY O.17791244 O.22492915 http://www.streetinsider.com/Press+Releases/Daiichi+Sankyo+Showcases+Progress+Across+Industry-Leading+Oncology+Portfolio+with+Latest+Research+Updates+at+ASCO/26560941.html <ul class="bwlistdisc"> <li> New analyses from five landmark trials of Enhertu® and Datroway® in breast and gastric cancer alongside pipeline data across other tumor types demonstrate continued oncology leadership </li> <li> Early phase trials-in-progress featuring potential medicines with novel mechanisms highlight the company’s commitment to identifying new breakthrough generating technologies for patients with cancer </li> </ul> <p> TOKYO--(BUSINESS WIRE)-- Daiichi Sankyo (TSE: 4568) will present new clinical research across its oncology portfolio with more than 25 abstracts in multiple cancers at the 2026 American Society of Clinical Oncology Annual Meeting (#ASCO26). </p><p> Data at ASCO will highlight the company’s progress toward advancing new standards of care for patients http://www.streetinsider.com/Press+Releases/Daiichi+Sankyo+Showcases+Progress+Across+Industry-Leading+Oncology+Portfolio+with+Latest+Research+Updates+at+ASCO/26560941.html Thu, 28 May 2026 07:00:00 -0400 4568 4568 DSNKY O.17791244 O.22492915 http://www.streetinsider.com/Press+Releases/Daiichi+Sankyo+Showcases+Progress+Across+Industry-Leading+Oncology+Portfolio+with+Latest+Research+Updates+at+ASCO/26560941.html <ul class="bwlistdisc"> <li> New analyses from five landmark trials of Enhertu® and Datroway® in breast and gastric cancer alongside pipeline data across other tumor types demonstrate continued oncology leadership </li> <li> Early phase trials-in-progress featuring potential medicines with novel mechanisms highlight the company’s commitment to identifying new breakthrough generating technologies for patients with cancer </li> </ul> <p> TOKYO--(BUSINESS WIRE)-- Daiichi Sankyo (TSE: 4568) will present new clinical research across its oncology portfolio with more than 25 abstracts in multiple cancers at the 2026 American Society of Clinical Oncology Annual Meeting (#ASCO26). </p><p> Data at ASCO will highlight the company’s progress toward advancing new standards of care for patients http://www.streetinsider.com/Press+Releases/Daiichi+Sankyo+Showcases+Progress+Across+Industry-Leading+Oncology+Portfolio+with+Latest+Research+Updates+at+ASCO/26560941.html Thu, 28 May 2026 07:00:00 -0400 4568 4568 DSNKY O.17791244 O.22492915 http://www.streetinsider.com/Business+Wire/Daiichi+Sankyo+Showcases+Progress+Across+Industry-Leading+Oncology+Portfolio+with+Latest+Research+Updates+at+ASCO/26560941.html <ul class="bwlistdisc"> <li> New analyses from five landmark trials of Enhertu® and Datroway® in breast and gastric cancer alongside pipeline data across other tumor types demonstrate continued oncology leadership </li> <li> Early phase trials-in-progress featuring potential medicines with novel mechanisms highlight the company’s commitment to identifying new breakthrough generating technologies for patients with cancer </li> </ul> <p> TOKYO--(BUSINESS WIRE)-- Daiichi Sankyo (TSE: 4568) will present new clinical research across its oncology portfolio with more than 25 abstracts in multiple cancers at the 2026 American Society of Clinical Oncology Annual Meeting (#ASCO26). </p><p> Data at ASCO will highlight the company’s progress toward advancing new standards of care for patients http://www.streetinsider.com/Business+Wire/Daiichi+Sankyo+Showcases+Progress+Across+Industry-Leading+Oncology+Portfolio+with+Latest+Research+Updates+at+ASCO/26560941.html Thu, 28 May 2026 07:00:00 -0400 4568 4568 DSNKY O.17791244 O.22492915 http://www.streetinsider.com/Business+Wire/Daiichi+Sankyo+Showcases+Progress+Across+Industry-Leading+Oncology+Portfolio+with+Latest+Research+Updates+at+ASCO/26560941.html <ul class="bwlistdisc"> <li> New analyses from five landmark trials of Enhertu® and Datroway® in breast and gastric cancer alongside pipeline data across other tumor types demonstrate continued oncology leadership </li> <li> Early phase trials-in-progress featuring potential medicines with novel mechanisms highlight the company’s commitment to identifying new breakthrough generating technologies for patients with cancer </li> </ul> <p> TOKYO--(BUSINESS WIRE)-- Daiichi Sankyo (TSE: 4568) will present new clinical research across its oncology portfolio with more than 25 abstracts in multiple cancers at the 2026 American Society of Clinical Oncology Annual Meeting (#ASCO26). </p><p> Data at ASCO will highlight the company’s progress toward advancing new standards of care for patients http://www.streetinsider.com/Business+Wire/Daiichi+Sankyo+Showcases+Progress+Across+Industry-Leading+Oncology+Portfolio+with+Latest+Research+Updates+at+ASCO/26560941.html Thu, 28 May 2026 07:00:00 -0400 4568 4568 DSNKY O.17791244 O.22492915 http://www.streetinsider.com/Business+Wire/Daiichi+Sankyo+Showcases+Progress+Across+Industry-Leading+Oncology+Portfolio+with+Latest+Research+Updates+at+ASCO/26560941.html <ul class="bwlistdisc"> <li> New analyses from five landmark trials of Enhertu® and Datroway® in breast and gastric cancer alongside pipeline data across other tumor types demonstrate continued oncology leadership </li> <li> Early phase trials-in-progress featuring potential medicines with novel mechanisms highlight the company’s commitment to identifying new breakthrough generating technologies for patients with cancer </li> </ul> <p> TOKYO--(BUSINESS WIRE)-- Daiichi Sankyo (TSE: 4568) will present new clinical research across its oncology portfolio with more than 25 abstracts in multiple cancers at the 2026 American Society of Clinical Oncology Annual Meeting (#ASCO26). </p><p> Data at ASCO will highlight the company’s progress toward advancing new standards of care for patients http://www.streetinsider.com/Business+Wire/Daiichi+Sankyo+Showcases+Progress+Across+Industry-Leading+Oncology+Portfolio+with+Latest+Research+Updates+at+ASCO/26560941.html Thu, 28 May 2026 07:00:00 -0400 4568 4568 DSNKY O.17791244 O.22492915 http://www.streetinsider.com/Business+Wire/Daiichi+Sankyo+Showcases+Progress+Across+Industry-Leading+Oncology+Portfolio+with+Latest+Research+Updates+at+ASCO/26560941.html <ul class="bwlistdisc"> <li> New analyses from five landmark trials of Enhertu® and Datroway® in breast and gastric cancer alongside pipeline data across other tumor types demonstrate continued oncology leadership </li> <li> Early phase trials-in-progress featuring potential medicines with novel mechanisms highlight the company’s commitment to identifying new breakthrough generating technologies for patients with cancer </li> </ul> <p> TOKYO--(BUSINESS WIRE)-- Daiichi Sankyo (TSE: 4568) will present new clinical research across its oncology portfolio with more than 25 abstracts in multiple cancers at the 2026 American Society of Clinical Oncology Annual Meeting (#ASCO26). </p><p> Data at ASCO will highlight the company’s progress toward advancing new standards of care for patients http://www.streetinsider.com/Business+Wire/Daiichi+Sankyo+Showcases+Progress+Across+Industry-Leading+Oncology+Portfolio+with+Latest+Research+Updates+at+ASCO/26560941.html Thu, 28 May 2026 07:00:00 -0400 4568 4568 DSNKY O.17791244 O.22492915 http://www.streetinsider.com/Business+Wire/Daiichi+Sankyo+Showcases+Progress+Across+Industry-Leading+Oncology+Portfolio+with+Latest+Research+Updates+at+ASCO/26560941.html <ul class="bwlistdisc"> <li> New analyses from five landmark trials of Enhertu® and Datroway® in breast and gastric cancer alongside pipeline data across other tumor types demonstrate continued oncology leadership </li> <li> Early phase trials-in-progress featuring potential medicines with novel mechanisms highlight the company’s commitment to identifying new breakthrough generating technologies for patients with cancer </li> </ul> <p> TOKYO--(BUSINESS WIRE)-- Daiichi Sankyo (TSE: 4568) will present new clinical research across its oncology portfolio with more than 25 abstracts in multiple cancers at the 2026 American Society of Clinical Oncology Annual Meeting (#ASCO26). </p><p> Data at ASCO will highlight the company’s progress toward advancing new standards of care for patients http://www.streetinsider.com/Business+Wire/Daiichi+Sankyo+Showcases+Progress+Across+Industry-Leading+Oncology+Portfolio+with+Latest+Research+Updates+at+ASCO/26560941.html Thu, 28 May 2026 07:00:00 -0400 4568 4568 DSNKY O.17791244 O.22492915 http://www.streetinsider.com/Press+Releases/Daiichi+Sankyo+Europe+Reaffirms+Commitment+to+Patient-Centred+Care+with+Extensive+Data+Showcase+at+EAS+Congress+2026/26547691.html <ul class="bwlistdisc"> <li> Presentations at the 94th European Atherosclerosis Society (EAS) Congress highlight the breadth of evidence for bempedoic acid across a wide range of patient subgroups and background therapies. </li> <li> Real-world data from the MILOS study across multiple European cohorts demonstrate consistent effectiveness and safety profile in routine clinical practice.1,2,3,4 </li> <li> Analysis from the CLEAR Outcomes trial underscores the impact of bempedoic acid on cardiovascular risks, including stroke and venous thromboembolism (VTE).5,6 </li> <li> Daiichi Sankyo Europe’s commitment to &quot;care for every heartbeat&quot; is centred on providing accessible oral treatment options to ensure every patient is given a chance to reach their LDL-C goals. </li> </ul> <p> MUNICH--(BUSINESS http://www.streetinsider.com/Press+Releases/Daiichi+Sankyo+Europe+Reaffirms+Commitment+to+Patient-Centred+Care+with+Extensive+Data+Showcase+at+EAS+Congress+2026/26547691.html Tue, 26 May 2026 11:00:00 -0400 4568 4568 A.31066700 A.40047721 DSNKY O.00277477 O.17791244 O.22422661 O.22492915 http://www.streetinsider.com/Press+Releases/Daiichi+Sankyo+Europe+Reaffirms+Commitment+to+Patient-Centred+Care+with+Extensive+Data+Showcase+at+EAS+Congress+2026/26547691.html <ul class="bwlistdisc"> <li> Presentations at the 94th European Atherosclerosis Society (EAS) Congress highlight the breadth of evidence for bempedoic acid across a wide range of patient subgroups and background therapies. </li> <li> Real-world data from the MILOS study across multiple European cohorts demonstrate consistent effectiveness and safety profile in routine clinical practice.1,2,3,4 </li> <li> Analysis from the CLEAR Outcomes trial underscores the impact of bempedoic acid on cardiovascular risks, including stroke and venous thromboembolism (VTE).5,6 </li> <li> Daiichi Sankyo Europe’s commitment to &quot;care for every heartbeat&quot; is centred on providing accessible oral treatment options to ensure every patient is given a chance to reach their LDL-C goals. </li> </ul> <p> MUNICH--(BUSINESS http://www.streetinsider.com/Press+Releases/Daiichi+Sankyo+Europe+Reaffirms+Commitment+to+Patient-Centred+Care+with+Extensive+Data+Showcase+at+EAS+Congress+2026/26547691.html Tue, 26 May 2026 11:00:00 -0400 4568 4568 A.31066700 A.40047721 DSNKY O.00277477 O.17791244 O.22422661 O.22492915 http://www.streetinsider.com/Press+Releases/Daiichi+Sankyo+Europe+Reaffirms+Commitment+to+Patient-Centred+Care+with+Extensive+Data+Showcase+at+EAS+Congress+2026/26547691.html <ul class="bwlistdisc"> <li> Presentations at the 94th European Atherosclerosis Society (EAS) Congress highlight the breadth of evidence for bempedoic acid across a wide range of patient subgroups and background therapies. </li> <li> Real-world data from the MILOS study across multiple European cohorts demonstrate consistent effectiveness and safety profile in routine clinical practice.1,2,3,4 </li> <li> Analysis from the CLEAR Outcomes trial underscores the impact of bempedoic acid on cardiovascular risks, including stroke and venous thromboembolism (VTE).5,6 </li> <li> Daiichi Sankyo Europe’s commitment to &quot;care for every heartbeat&quot; is centred on providing accessible oral treatment options to ensure every patient is given a chance to reach their LDL-C goals. </li> </ul> <p> MUNICH--(BUSINESS http://www.streetinsider.com/Press+Releases/Daiichi+Sankyo+Europe+Reaffirms+Commitment+to+Patient-Centred+Care+with+Extensive+Data+Showcase+at+EAS+Congress+2026/26547691.html Tue, 26 May 2026 11:00:00 -0400 4568 4568 A.31066700 A.40047721 DSNKY O.00277477 O.17791244 O.22422661 O.22492915 http://www.streetinsider.com/Press+Releases/Daiichi+Sankyo+Europe+Reaffirms+Commitment+to+Patient-Centred+Care+with+Extensive+Data+Showcase+at+EAS+Congress+2026/26547691.html <ul class="bwlistdisc"> <li> Presentations at the 94th European Atherosclerosis Society (EAS) Congress highlight the breadth of evidence for bempedoic acid across a wide range of patient subgroups and background therapies. </li> <li> Real-world data from the MILOS study across multiple European cohorts demonstrate consistent effectiveness and safety profile in routine clinical practice.1,2,3,4 </li> <li> Analysis from the CLEAR Outcomes trial underscores the impact of bempedoic acid on cardiovascular risks, including stroke and venous thromboembolism (VTE).5,6 </li> <li> Daiichi Sankyo Europe’s commitment to &quot;care for every heartbeat&quot; is centred on providing accessible oral treatment options to ensure every patient is given a chance to reach their LDL-C goals. </li> </ul> <p> MUNICH--(BUSINESS http://www.streetinsider.com/Press+Releases/Daiichi+Sankyo+Europe+Reaffirms+Commitment+to+Patient-Centred+Care+with+Extensive+Data+Showcase+at+EAS+Congress+2026/26547691.html Tue, 26 May 2026 11:00:00 -0400 4568 4568 A.31066700 A.40047721 DSNKY O.00277477 O.17791244 O.22422661 O.22492915 http://www.streetinsider.com/Press+Releases/Daiichi+Sankyo+Europe+Reaffirms+Commitment+to+Patient-Centred+Care+with+Extensive+Data+Showcase+at+EAS+Congress+2026/26547691.html <ul class="bwlistdisc"> <li> Presentations at the 94th European Atherosclerosis Society (EAS) Congress highlight the breadth of evidence for bempedoic acid across a wide range of patient subgroups and background therapies. </li> <li> Real-world data from the MILOS study across multiple European cohorts demonstrate consistent effectiveness and safety profile in routine clinical practice.1,2,3,4 </li> <li> Analysis from the CLEAR Outcomes trial underscores the impact of bempedoic acid on cardiovascular risks, including stroke and venous thromboembolism (VTE).5,6 </li> <li> Daiichi Sankyo Europe’s commitment to &quot;care for every heartbeat&quot; is centred on providing accessible oral treatment options to ensure every patient is given a chance to reach their LDL-C goals. </li> </ul> <p> MUNICH--(BUSINESS http://www.streetinsider.com/Press+Releases/Daiichi+Sankyo+Europe+Reaffirms+Commitment+to+Patient-Centred+Care+with+Extensive+Data+Showcase+at+EAS+Congress+2026/26547691.html Tue, 26 May 2026 11:00:00 -0400 4568 4568 A.31066700 A.40047721 DSNKY O.00277477 O.17791244 O.22422661 O.22492915 http://www.streetinsider.com/Press+Releases/Daiichi+Sankyo+Europe+Reaffirms+Commitment+to+Patient-Centred+Care+with+Extensive+Data+Showcase+at+EAS+Congress+2026/26547691.html <ul class="bwlistdisc"> <li> Presentations at the 94th European Atherosclerosis Society (EAS) Congress highlight the breadth of evidence for bempedoic acid across a wide range of patient subgroups and background therapies. </li> <li> Real-world data from the MILOS study across multiple European cohorts demonstrate consistent effectiveness and safety profile in routine clinical practice.1,2,3,4 </li> <li> Analysis from the CLEAR Outcomes trial underscores the impact of bempedoic acid on cardiovascular risks, including stroke and venous thromboembolism (VTE).5,6 </li> <li> Daiichi Sankyo Europe’s commitment to &quot;care for every heartbeat&quot; is centred on providing accessible oral treatment options to ensure every patient is given a chance to reach their LDL-C goals. </li> </ul> <p> MUNICH--(BUSINESS http://www.streetinsider.com/Press+Releases/Daiichi+Sankyo+Europe+Reaffirms+Commitment+to+Patient-Centred+Care+with+Extensive+Data+Showcase+at+EAS+Congress+2026/26547691.html Tue, 26 May 2026 11:00:00 -0400 4568 4568 A.31066700 A.40047721 DSNKY O.00277477 O.17791244 O.22422661 O.22492915 http://www.streetinsider.com/Press+Releases/Daiichi+Sankyo+Europe+Reaffirms+Commitment+to+Patient-Centred+Care+with+Extensive+Data+Showcase+at+EAS+Congress+2026/26547691.html <ul class="bwlistdisc"> <li> Presentations at the 94th European Atherosclerosis Society (EAS) Congress highlight the breadth of evidence for bempedoic acid across a wide range of patient subgroups and background therapies. </li> <li> Real-world data from the MILOS study across multiple European cohorts demonstrate consistent effectiveness and safety profile in routine clinical practice.1,2,3,4 </li> <li> Analysis from the CLEAR Outcomes trial underscores the impact of bempedoic acid on cardiovascular risks, including stroke and venous thromboembolism (VTE).5,6 </li> <li> Daiichi Sankyo Europe’s commitment to &quot;care for every heartbeat&quot; is centred on providing accessible oral treatment options to ensure every patient is given a chance to reach their LDL-C goals. </li> </ul> <p> MUNICH--(BUSINESS http://www.streetinsider.com/Press+Releases/Daiichi+Sankyo+Europe+Reaffirms+Commitment+to+Patient-Centred+Care+with+Extensive+Data+Showcase+at+EAS+Congress+2026/26547691.html Tue, 26 May 2026 11:00:00 -0400 4568 4568 A.31066700 A.40047721 DSNKY O.00277477 O.17791244 O.22422661 O.22492915 http://www.streetinsider.com/Press+Releases/Daiichi+Sankyo+Europe+Reaffirms+Commitment+to+Patient-Centred+Care+with+Extensive+Data+Showcase+at+EAS+Congress+2026/26547691.html <ul class="bwlistdisc"> <li> Presentations at the 94th European Atherosclerosis Society (EAS) Congress highlight the breadth of evidence for bempedoic acid across a wide range of patient subgroups and background therapies. </li> <li> Real-world data from the MILOS study across multiple European cohorts demonstrate consistent effectiveness and safety profile in routine clinical practice.1,2,3,4 </li> <li> Analysis from the CLEAR Outcomes trial underscores the impact of bempedoic acid on cardiovascular risks, including stroke and venous thromboembolism (VTE).5,6 </li> <li> Daiichi Sankyo Europe’s commitment to &quot;care for every heartbeat&quot; is centred on providing accessible oral treatment options to ensure every patient is given a chance to reach their LDL-C goals. </li> </ul> <p> MUNICH--(BUSINESS http://www.streetinsider.com/Press+Releases/Daiichi+Sankyo+Europe+Reaffirms+Commitment+to+Patient-Centred+Care+with+Extensive+Data+Showcase+at+EAS+Congress+2026/26547691.html Tue, 26 May 2026 11:00:00 -0400 4568 4568 A.31066700 A.40047721 DSNKY O.00277477 O.17791244 O.22422661 O.22492915 http://www.streetinsider.com/Press+Releases/Daiichi+Sankyo+Europe+Reaffirms+Commitment+to+Patient-Centred+Care+with+Extensive+Data+Showcase+at+EAS+Congress+2026/26547691.html <ul class="bwlistdisc"> <li> Presentations at the 94th European Atherosclerosis Society (EAS) Congress highlight the breadth of evidence for bempedoic acid across a wide range of patient subgroups and background therapies. </li> <li> Real-world data from the MILOS study across multiple European cohorts demonstrate consistent effectiveness and safety profile in routine clinical practice.1,2,3,4 </li> <li> Analysis from the CLEAR Outcomes trial underscores the impact of bempedoic acid on cardiovascular risks, including stroke and venous thromboembolism (VTE).5,6 </li> <li> Daiichi Sankyo Europe’s commitment to &quot;care for every heartbeat&quot; is centred on providing accessible oral treatment options to ensure every patient is given a chance to reach their LDL-C goals. </li> </ul> <p> MUNICH--(BUSINESS http://www.streetinsider.com/Press+Releases/Daiichi+Sankyo+Europe+Reaffirms+Commitment+to+Patient-Centred+Care+with+Extensive+Data+Showcase+at+EAS+Congress+2026/26547691.html Tue, 26 May 2026 11:00:00 -0400 4568 4568 A.31066700 A.40047721 DSNKY O.00277477 O.17791244 O.22422661 O.22492915